{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:53:43Z","timestamp":1783090423496,"version":"3.54.6"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150415"],"award-info":[{"award-number":["AI150415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI145687"],"award-info":[{"award-number":["AI145687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI142596"],"award-info":[{"award-number":["AI142596"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI058607"],"award-info":[{"award-number":["AI058607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","award":["HR0011-17-2-0069"],"award-info":[{"award-number":["HR0011-17-2-0069"]}],"id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.cell.2020.05.041","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:50:10Z","timestamp":1590537010000},"page":"1458-1463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19"],"prefix":"10.1016","volume":"181","author":[{"given":"Gregory D.","family":"Sempowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin O.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Wiehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton F.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2020.05.041_bib1","article-title":"Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients","author":"Andreano","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cell.2020.05.041_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2020.05.041_bib4","series-title":"Press Release: COVID-19 Therapeutics Accelerator Awards $20 Million in Initial Grants to Fund Clinical Trials","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib5","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2020.05.041_bib6","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","author":"Brouwer","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.chom.2012.09.008","article-title":"A Blueprint for HIV Vaccine Discovery","volume":"12","author":"Burton","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2020.05.041_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.14235","article-title":"Vaccine innovations for emerging infectious diseases-a symposium report","volume":"1462","author":"Cable","year":"2020","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.cell.2020.05.041_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.aap7463","article-title":"The Global Virome Project","volume":"359","author":"Carroll","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2020.05.041_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2020.05.041_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2020.05.041_bib13","first-page":"eabc5312","article-title":"A strategic approach to COVID-19 vaccine R&D","author":"Corey","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib14","series-title":"Pandemic Prevention Platform (P3)","year":"2017"},{"key":"10.1016\/j.cell.2020.05.041_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cell.2020.05.041_bib16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/651603","article-title":"Pharmacologic advances in the treatment and prevention of respiratory syncytial virus","volume":"50","author":"Empey","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cell.2020.05.041_bib17","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cell.2020.05.041_bib18","series-title":"Next hCoV-19 App","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/epirev\/mxz012","article-title":"CEPI: Driving Progress Toward Epidemic Preparedness and Response","volume":"41","author":"Gouglas","year":"2019","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.cell.2020.05.041_bib20","first-page":"eabb8923","article-title":"Rapid COVID-19 vaccine development","author":"Graham","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jama.2018.0345","article-title":"Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases","volume":"319","author":"Graham","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2020.05.041_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.chom.2016.02.002","article-title":"HIV-Host Interactions: Implications for Vaccine Design","volume":"19","author":"Haynes","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2020.05.041_bib24","doi-asserted-by":"crossref","first-page":"eaaz2686","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies","volume":"11","author":"Haynes","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2020.05.041_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41467-019-14196-w","article-title":"Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements","volume":"11","author":"Henderson","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2020.05.041_bib26","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"Engineered antibodies with increased activity to recruit complement","volume":"166","author":"Idusogie","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib27","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc\u03b3R pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2020.05.041_bib28","article-title":"Potent human neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Ju","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1126\/science.368.6489.351","article-title":"NIH organizes hunt for drugs","volume":"368","author":"Kaiser","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib31","article-title":"Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2","author":"Korber","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib32","doi-asserted-by":"crossref","first-page":"eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647","article-title":"A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection","volume":"4","author":"Kose","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.immuni.2012.08.012","article-title":"Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies","volume":"37","author":"Kwong","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2020.05.041_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2020.05.041_bib35","doi-asserted-by":"crossref","first-page":"e1008026","DOI":"10.1371\/journal.ppat.1008026","article-title":"Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies","volume":"15","author":"LaBranche","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cell.2020.05.041_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2020.05.041_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jviromet.2009.02.014","article-title":"High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies","volume":"158","author":"Liao","year":"2009","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.cell.2020.05.041_bib38","doi-asserted-by":"crossref","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.cell.2020.05.041_bib39","series-title":"Los Alamos HIV Sequence Database","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib40","series-title":"SARS-CoV-2 Sequence Analysis Pipeline","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib41","article-title":"Comparison of SARS-CoV-2 infections among 3 species of non-human primates","author":"Lu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cell.2020.05.041_bib43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody responses to viral infections: a structural perspective across three different enveloped viruses","volume":"4","author":"Murin","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cell.2020.05.041_bib44","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.4161\/hv.26498","article-title":"Optimized and enhanced DNA plasmid vector based in\u00a0vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab","volume":"9","author":"Muthumani","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cell.2020.05.041_bib45","series-title":"Press Release: NIH clinical trial of investigational vaccine for COVID-19 begins","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2020.05.041_bib47","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2020.05.041_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2020.05.041_bib49","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1073\/pnas.2005456117","article-title":"News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine","volume":"117","author":"Peeples","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2020.05.041_bib50","article-title":"The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement","author":"Quinlan","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib51","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cell.2020.05.041_bib52","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cell.2020.05.041_bib53","first-page":"eabb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib54","article-title":"Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model","author":"Rogers","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib55","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cell.2020.05.041_bib56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib57","doi-asserted-by":"crossref","first-page":"eaay7199","DOI":"10.1126\/science.aay7199","article-title":"Targeted selection of HIV-specific antibody mutations by engineering B cell maturation","volume":"366","author":"Saunders","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib58","article-title":"Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual","author":"Seydoux","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2020.05.041_bib59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.cell.2020.05.041_bib60","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib61","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.cell.2020.05.041_bib62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2020.05.041_bib63","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cell.2020.05.041_bib64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2020.05.041_bib65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2020.05.041_bib66","doi-asserted-by":"crossref","first-page":"e02002","DOI":"10.1128\/JVI.02002-17","article-title":"Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape","volume":"92","author":"Wang","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2020.05.041_bib67","series-title":"Coronavirus disease (COVID-2019) technical guidance","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib68","series-title":"Draft landscape of COVID-19 candidate vaccines \u2013 20 March 2020","year":"2020"},{"key":"10.1016\/j.cell.2020.05.041_bib69","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.chom.2018.04.018","article-title":"Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development","volume":"23","author":"Wiehe","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2020.05.041_bib70","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib71","first-page":"61","article-title":"Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults","volume":"61","author":"Yu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cell.2020.05.041_bib72","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2020.05.041_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2020.05.041_bib74","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14760584.2018.1506702","article-title":"Prospects for a MERS-CoV spike vaccine","volume":"17","author":"Zhou","year":"2018","journal-title":"Expert Rev. Vaccines"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867420306747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867420306747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:35:00Z","timestamp":1778664900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867420306747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0092867420306747"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2020.05.041","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2020.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}